Sigyn Therapeutics (SIGY) Notes Payables (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Notes Payables of $181362.0 for Q3 2025, down 92.14% sequentially from $2.3 million in Q2 2025, and down 89.87% YoY from $1.8 million in Q3 2024.
Sigyn Therapeutics (SIGY) Notes Payables (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Notes Payables for 10 years, with the latest figure at $181362.0 in Q3 2025.
- Quarterly Notes Payables fell 89.87% year-over-year to $181362.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $181362.0 (down 89.87% YoY) and the FY2024 annual result came in at $174206.0, down 90.79% from the prior year.
- Notes Payables retreated to $181362.0 in Q3 2025 per SIGY's latest filing, from $2.3 million in the prior quarter.
- Over five years, Notes Payables peaked at $2.9 million in Q3 2023 and troughed at $174206.0 in Q4 2024.
- A 5-year average of $1.5 million and a median of $1.6 million in 2022 frame the typical range for Notes Payables.
- The sharpest annual moves came in 2021 and 2024: Notes Payables surged 532.77% in 2021, then sank 90.79% in 2024.
- Over 5 years, Notes Payables stood at $647202.0 in 2021, then jumped by 152.88% to $1.6 million in 2022, then gained by 15.59% to $1.9 million in 2023, then tumbled by 90.79% to $174206.0 in 2024, then climbed by 4.11% to $181362.0 in 2025.
- According to Business Quant data, Notes Payables over the past three periods registered $181362.0, $2.3 million, and $2.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 181,362.00 |
| Jun 30, 2025 | 2.31 Mn |
| Mar 31, 2025 | 2.19 Mn |
| Dec 31, 2024 | 174,206.00 |
| Sep 30, 2024 | 1.79 Mn |
| Jun 30, 2024 | 1.78 Mn |
| Mar 31, 2024 | 2.48 Mn |
| Dec 31, 2023 | 1.89 Mn |
| Sep 30, 2023 | 2.95 Mn |
| Jun 30, 2023 | 2.63 Mn |
| Mar 31, 2023 | 2.47 Mn |
| Dec 31, 2022 | 1.64 Mn |
| Sep 30, 2022 | 1.52 Mn |
| Jun 30, 2022 | 945,219.00 |
| Mar 31, 2022 | 704,920.00 |
| Dec 31, 2021 | 647,202.00 |
| Sep 30, 2021 | 684,743.00 |
| Jun 30, 2021 | 621,297.00 |
| Mar 31, 2021 | 578,254.00 |
| Dec 31, 2020 | 518,668.00 |